Home » Stocks » PLSE

Pulse Biosciences, Inc. (PLSE)

Stock Price: $21.03 USD -0.74 (-3.40%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 555.15M
Revenue (ttm) n/a
Net Income (ttm) -49.85M
Shares Out 23.25M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $21.03
Previous Close $21.77
Change ($) -0.74
Change (%) -3.40%
Day's Open 22.02
Day's Range 20.72 - 22.18
Day's Volume 87,214
52-Week Range 6.21 - 45.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial result...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellF...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first clini...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report finan...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technolog...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug A...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technolog...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technolog...

3 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™) technolo...

3 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology...

4 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scientific upd...

4 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate...

5 months ago - Business Wire

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report finan...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinical results...

6 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational ...

6 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receipt of Medic...

6 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

7 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

7 months ago - Business Wire

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPSu2122) technology, today announced that three clinic...

9 months ago - Business Wire

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Pulse Biosciences, Inc. (PLSE) Darrin Uecker on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pulse Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pulse BioSciences is the second instance Bob Duggan has taken the helm of a biotech that has fallen flat in an attempt to reinvigorate it.

1 year ago - Seeking Alpha

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
May 18, 2016
Stock Exchange
NASDAQ
Ticker Symbol
PLSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price forecast is 43.00.

Price Target
$43.00
Analyst Consensus: Buy